J.P. Morgan Asset Management taking initial stake in Newron Freitag, 31. Januar 2014 - 07:00

J.P. Morgan Asset Management taking initial stake in Newron

Milan, Italy - January 31, 2014 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announced that J.P. Morgan Asset Management has taken a 1.8% stake in the Company, subscribing to the 211,473 shares left over from the 2013 capital increase, by means of a private placement.

The subscription price was set at CHF 17.00 per share, representing a 2.7% premium to the closing price of Newron’s shares on January 24, 2014, of CHF 16.55. The proceeds will be used to further capitalise the Company and fund its pipeline development and clinical trials.

Stefan Weber, CEO, commented, “We are very pleased by the increasing interest in Newron from leading institutional investors, given the recent submission of the MAA for safinamide to the European Medicines Agency (EMA) and the work currently ongoing to complete the New Drug Application (NDA) submission to the US Food and Drug Administration (FDA). There is increasing interest in Newron’s promising pipeline of four Phase II compounds for orphan indications as well as its highly innovative add-on therapy for schizophrenia, currently in a Phase I trial.”

Closing of the transaction will be subject to customary Italian and Swiss regulatory requirements. The new shares will be listed and traded on the SIX Swiss Exchange under the same ISIN as the Company’s existing shares (ISIN: IT0004147952) on or about February 3, 2014.

Financial Calendar 2014

Publication of Annual Report 2013	March 4, 2014
Press and Analyst Conference	March 4, 2014, Zürich
Information event for shareholders	March 4, 2014, Zürich
Annual Shareholders’ meeting	March 27, 2014, Milan
Publication of Half-Year Report 2014	September 16, 2014

About Newron Pharmaceuticals

Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS) and pain. The Company is headquartered in Bresso near Milan, Italy. Based on the phase III results of safinamide for the treatment of Parkinson’s disease, Newron is working to complete the global filing of the compound, together with its partners. Zambon Group has the rights to commercialise safinamide globally, excluding Japan and other key Asian territories, and Meiji Seika has the rights to develop and commercialise safinamide in Japan and other key Asian territories. Newron’s additional projects are primarily addressed towards highly promising treatments for rare disease patients and are at various stages of clinical development, including sNN0031 for patients with Parkinson’s disease non-responsive to oral drug treatments, sarizotan for patients with Rett’s syndrome, sNN0029 for patients with ALS, ralfinamide for patients with specific pain indications, and NW-3509 as potential first add-on therapy for the treatment of patients with schizophrenia. www.newron.com

For more information, contact:

Media

Investors and analysts

Italy

Stefan Weber - CEO

Phone: +39 02 6103 46 26

E-mail: pr@newron.com

UK/Global media

Julia Phillips

FTI Consulting

Phone: +44 (0) 20 7269 7187

Switzerland

Martin Meier-Pfister IRF Communications

Phone: +41 43 244 81 40

Stefan Weber - CEO

Phone: +39 02 6103 46 30

E-mail: ir@newron.com

Important Notices

This document contains forward-looking statements, including (withoutlimitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates and current and future collaborations for the development and commercialisation of its product candidates and reduce costs (including staff costs), (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s anticipated future revenues, capital expenditures and financial resources, and (4) assumptions underlying any such statements. In some cases these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”,“believe”, “target”,and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements.

By their very nature,such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and otheroutcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions.

Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programmes, development activities, commercialisation plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions.

Newron does not undertake any obligation to publicly up-date or revise forward looking statements except as may be required by applicable regulations of the SIX Swiss Exchange where the shares of Newron are listed.

This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with anycontract or commitment whatsoever.